Solar Stock Ersol Rises on Bosch Deal
Jun 3rd, 2008 | By Contrarian Profits | Category: Featured, Financial NewsSolar stock Ersol rose to a new record after German engineering giant Bosch said it paid $157 a share, a premium of more than 60%, for a controlling stake in the company. This from The Guardian:
Shares in leading German solar stocks rose substantially on expectations that other big players, including oil groups, are on the prowl in a market that grew to €6.6bn last year and is forecast to top €18bn by 2020.
Germany is by far the world’s biggest solar energy market thanks to its “feed-in” tariffs, which pay a government-guaranteed premium of up to €0.47 a kilowatt hour for power produced by photovoltaic panels. It is expected to continue to grow despite government plans to cut subsidies by 8% or 9% in 2009 and 2010.
“The richest investment opportunities can be found in the fast-emerging alternative energy sector,” says Mike Burnick in The Offshore A-Letter.
“That’s where oilman T. Boone Pickens is putting his money – his company Mesa Power just placed an order for US$2 billion in wind turbines. And there’s much more profit potential in other parts of the alternative energy sector too – especially alternative fuel.
“The market for ALL alternative energy sources grew 40% last year alone to US$77.3 billion and will explode into a US$250 billion industry within 10 years.
“Bio-fuel grew to a US$25.4 billion market last with more than 15 billion gallons of ethanol and biodiesel produced globally – more than double the output of just four years ago. The worldwide Bio-fuel industry will continue to enjoy explosive growth for years to come – expanding into a US$81 billion business within the next 10-years!”
Advertisement
It could become the bestselling pill in medical history...
On March 30 - there’ll be an announcement of FDA results for a new drug that many experts believe could make early investors $195,600, overnight, and potentially even more.
One analyst writes, “This is the kind of situation that can literally change your life.” Forbes says, “It could be a billion-dollar drug.”